Accessibility Menu
Pulse Biosciences logo

Pulse Biosciences(NASDAQ) PLSE

Current Price$31.21
Market Cap$2.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+686%
5 Year+63%
1 Year+116%
1 Month+27%
Pulse Biosciences last closing stock price
MetricPriceDate
Last closeUSD 32.762026-07-22
Pulse Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+24.47%USD 26.322026-07-15
1 month+27.42%USD 25.712026-06-22
3 month+35.09%USD 24.252026-04-23
Year to date+138.6%USD 13.732025-12-31
1 year+116.09%USD 15.162025-07-22
3 year+392.63%USD 6.652023-07-21
5 year+63.31%USD 20.062021-07-23
Since inception+685.61%USD 4.172016-05-18

Pulse Biosciences Financials at a Glance

Market Cap

$2.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$751.00K

Net Income (TTM)

-$74.57M

EPS (TTM)

-$1.10

P/E Ratio

-29.70

Dividend

$0.00

Beta (Volatility)

1.43 (Average)

Price

$31.21

Volume

4,123

Open

$32.13

Previous Close

$32.76

Daily Range

$30.67 - $32.53

52-Week Range

$12.56 - $33.87

Estimated Earnings Date

Aug 11, 2026

PLSE News

BuyAlert-Green.png

Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.

Robert IzquierdoMay 17, 2026
Foolcom-Featured.png

Pulse Biosciences Cash Jumps in Q2

Motley Fool Markets TeamAug 12, 2025
dermatologist

Why Pulse Biosciences Stock Moved Higher Thursday

James HalleyJul 1, 2021
ALK aircraft

Why Alaska Air Group, Pulse Biosciences, and BJ's Restaurants Jumped Today

Dan CaplingerApr 13, 2018

PLSE: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pulse Biosciences

Pulse makes tools to treat diseases with electricity. These devices use short energy pulses to clear cells. This helps doctors treat heart and soft tissue issues.

Precision Tools for Target Cells

  • Vybrance System: Needle electrode used for the non-thermal destruction of soft tissue such as thyroid nodules.
  • Cardiac Surgical Clamp: Ablation tool designed for heart surgeons to treat irregular heartbeats called atrial fibrillation.
  • Cardiac Catheter: Circular treatment device used by heart specialists to reach tissue through the blood vessels.
  • nPulse Console: Software-enabled base station that powers different treatment attachments for various medical procedures.

Pivots and Regulatory Wins

  • Received clearance from the U.S. Food and Drug Administration for the Vybrance system in March 2024.
  • Shifted the primary business focus from skin treatments to heart health in September 2022.
  • Obtained Breakthrough Device Designation for the cardiac surgery system in July 2024 to speed up development.
  • Started the PRECISE BTN clinical trial to study thyroid nodule treatments in September 2025.
  • Received approval for an Investigational Device Exemption to begin heart catheter studies in December 2025.

The Non-Thermal Advantage

The company uses Nano-pulse Stimulation technology to clear cells without using heat, which protects healthy surrounding tissue. It holds over 250 issued patents to protect this unique method of delivering electrical energy.

The 2025 Fiscal Snapshot

  • Revenue reached $264,000 in Q4 2025, up from zero in Q4 2024.
  • Net income was -$17.4 million in Q4 2025, which narrowed by 10.1% year-over-year.
  • Operating income hit -$18.3 million in Q4 2025, an improvement of 9.9% from Q4 2024.
  • Free cash flow hit -$14.9 million in Q4 2025, a 61.6% deeper loss compared to Q4 2024.

Bottom Line

Pulse has transitioned from a skincare focus to developing high-stakes surgical tools for heart and soft tissue repair. Its long-term viability depends on moving these products from clinical testing into full commercial use.

AI Generated • May 1, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

116

CEO

Paul A. LaViolette, MBA

Website

www.pulsebiosciences.com

Headquarters

Miami, FL 94545, US

PLSE Financials

Key Financial Metrics (TTM)

Gross Margin

-91.08%

Operating Margin

-10392.14%

Net Income Margin

-9929.03%

Return on Equity

-86.67%

Return on Capital

-87.25%

Return on Assets

-91.36%

Earnings Yield

-3.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

69.21M

Volume

4.12K

Avg. Volume

346.50K

Financials (TTM)

Gross Profit

-$684.00K

Operating Income

-$78.05M

EBITDA

-$74.10M

Operating Cash Flow

-$55.20M

Capital Expenditure

-$303.00K

Free Cash Flow

-$55.50M

Cash & ST Invst.

$68.32M

Total Debt

$7.16M

Pulse Biosciences Performance Analysis

Pulse Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 700,000-50.6%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 350,000N/A
Pulse Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31207.0%
Q12026-03-3151.9%
Pulse Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.72-24.3%
20232023-12-31USD -0.88-49.0%
20242024-12-31USD -0.924.4%
20252025-12-31USD -1.0817.7%
Pulse Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-12.0%
Q32025-09-30-3.6%
Q42025-12-3110.3%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$401.00K

N/A

Gross Profit

$31.00K

N/A

Gross Margin

7.73%

N/A

Market Cap

$2.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$19.55M

N/A

Employees

116

N/A

Net Income

-$18.58M

-10.6%

EBITDA

-$18.90M

-14.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$68.32M

-42.7%

Total Debt

$7.16M

-16.6%

Accounts Receivable

$157.00K

N/A

Inventory

$206.00K

+586.7%

Long Term Debt

$5.53M

-22.9%

Short Term Debt

$1.63M

+15.7%

Return on Assets

-91.36%

N/A

Return on Invested Capital

-1.09%

N/A

Free Cash Flow

-$14.63M

-7.8%

Operating Cash Flow

-$14.60M

-7.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVCRNovocure Ltd
$19.97+28.26%
ATAIAtai Beckley Inc.
$7.18-0.07%
NKTRNektar Therapeutics
$68.73-0.85%
IMTXImmatics N.V.
$9.32+1.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.88-0.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.16+0.05%
HBANHuntington Bancshares
$17.38-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$37.03+0.08%

Questions About PLSE

What is the current price of Pulse Biosciences?

Pulse Biosciences is trading at $31.21 per share.

What is the 52-week range for Pulse Biosciences?

Over the past 52 weeks, Pulse Biosciences has traded between $12.56 and $33.87.

How much debt does Pulse Biosciences have?

As of the most recent reporting period, Pulse Biosciences reported total debt of $7.16M.

How much cash does Pulse Biosciences have on hand?

Pulse Biosciences reported $68.32M in cash and cash equivalents in its most recent financial results.

What is Pulse Biosciences’s dividend yield?

Pulse Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services